Top Markets
#1 bitcastle Token bitcastle Token +151.43%
#2 MarsCoin MarsCoin +70.18%
#3 Palladium Network Palladium Network +53.05%
#4 Siren Siren +28.27%
#5 edgeX edgeX +23.02%
#6 Status Status +20.93%
#7 Useless Coin Useless Coin +18.68%
#8 Bedrock Bedrock +18.28%
#9 PondCoin PondCoin +15.49%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
Coin of the day
bitcastle Token bitcastle Token
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Classifica tra le azioni #18406
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Prezzo delle azioni
$5.81
Ultima sincronizzazione: 2023-02-28
Capitalizzazione di mercato
$200.14M
Variazione (1 giorno)
-0.34%
Variazione (1 anno)
0.00%
Paese
US
Scambia KemPharm, Inc. (KMPH)

Categoria

Healthcare
Utile per KemPharm, Inc. (KMPH)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di KemPharm, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di KemPharm, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH